Added to YB: 2025-05-13
Pitch date: 2025-05-08
ZTS [neutral]
Zoetis Inc.
-20.27%
current return
Author Info
Best Anchor Stocks shares deep research on companies with long-term potential aThe Bear Cavend lower-than-average volatility. Sign up for the newsletter.
Company Info
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Market Cap
$53.0B
Pitch Price
$159.63
Price Target
N/A
Dividend
1.69%
EV/EBITDA
14.37
P/E
20.86
EV/Sales
6.34
Sector
Pharmaceuticals
Category
N/A
Market overreaction or justified drop? - Zoetis' Q1 Earnings Analysis
ZTS (earnings update): Q1 shows 9% organic rev growth, 1% reported (MFA divestiture/FX -800bps). Margins up ~150bps post-livestock divestiture. Buying back 83% of FCF ($2B/12mo) reducing shares 2.4% YoY. Tariffs cost $20M. Simparica (+19%) & Apoquel (+10%) strong despite competition. Librela growing 17% in US but below expectations - management cites weak chronic med spending & poor awareness.
Read full article (7 min)